Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445965 · ClinicalTrials.gov registry record · Phase 2
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00445965: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00445965 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445965, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases. PURPOSE: This phase II trial is studying the side effects and how well iodine I 131 monoclonal antibody 3F8 works in treating patients with central nervous system cancer or leptomeningeal cancer.
Interventions
- OTHER pharmacological study
- GENETIC DNA analysis
- RADIATION iodine I 131 monoclonal antibody 3F8
- OTHER immunologic technique
- RADIATION 131I-3F8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2006-01 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445965
The ClinicalTrials.gov registry entry for NCT00445965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00445965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00445965 about?
NCT00445965 is a clinical study titled "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer". RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases. PURPOSE: This...
What is the current status of trial NCT00445965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2006-01. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT00445965?
The interventions under investigation include: pharmacological study (OTHER), DNA analysis (GENETIC), iodine I 131 monoclonal antibody 3F8 (RADIATION), immunologic technique (OTHER), 131I-3F8 (RADIATION).
Who is sponsoring clinical trial NCT00445965?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.